Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Catherine Guly

Showing results (1-10 of 15) with videos related to

Pageof 2
Sort By:
Annals of the Rheumatic Diseases|March 2, 2018
Adalimumab for childhood onset uveitisA V Ramanan, Catherine Guly
BMJ (Clinical Research Ed.)|December 3, 2005
Challenges of private provision in the NHS: treatment centres and their effect on surgical trainingCatherine Guly, Richard Sidebottom, Kim Hakin, et al.
Rheumatology Advances in Practice|September 22, 2022
Comment on: Benchmarking tocilizumab use for giant cell arteritisShalini Janagan, Catherine Guly, Sarah Skeoch, et al.
Practical Neurology|February 13, 2014
Eye drop neurologyLuke Bennetto, Catherine Guly, Ian Ormerod, et al.
Archives of Disease in Childhood|October 10, 2013
Unilateral neuroretinitis secondary to Bartonella henselae infectionAnna Catherine Kilonback, Catherine Guly, Jolanta Bernatoniene, et al.
American Journal of Ophthalmology|November 5, 2017
Uveitis and Juvenile Psoriatic Arthritis or PsoriasisSherveen S Salek, Archana Pradeep, Catherine Guly, et al.
Ocular Immunology and Inflammation|February 21, 2023
Childhood Chronic Idiopathic Uveitis in a Multicentre International CohortIlaria Maccora, Catherine Guly, Cinzia de Libero, et al.
Pediatric Rheumatology Online Journal|October 6, 2019
Same but different? A thematic analysis on adalimumab biosimilar switching among patients with juvenile idiopathic arthritisWilliam D Renton, Helen Leveret, Catherine Guly, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|February 10, 2026
Treatment of a large cohort of childhood chronic non-infectious uveitis a multicentric large study: adalimumab versus methotrexate as first line therapyIlaria Maccora, Catherine Guly, Cinzia de Libero, et al.
BMC Rheumatology|March 20, 2019
A phase II trial protocol of Tocilizumab in anti-TNF refractory patients with JIA-associated uveitis (the APTITUDE trial)Athimalaipet V Ramanan, Andrew D Dick, Ashley P Jones, et al.
Pageof 2

Showing results (1-10 of 15) with videos related to

Sort By:
Pageof 2
Annals of the Rheumatic Diseases|March 2, 2018
Adalimumab for childhood onset uveitisA V Ramanan, Catherine Guly
BMJ (Clinical Research Ed.)|December 3, 2005
Challenges of private provision in the NHS: treatment centres and their effect on surgical trainingCatherine Guly, Richard Sidebottom, Kim Hakin, et al.
Rheumatology Advances in Practice|September 22, 2022
Comment on: Benchmarking tocilizumab use for giant cell arteritisShalini Janagan, Catherine Guly, Sarah Skeoch, et al.
Practical Neurology|February 13, 2014
Eye drop neurologyLuke Bennetto, Catherine Guly, Ian Ormerod, et al.
Archives of Disease in Childhood|October 10, 2013
Unilateral neuroretinitis secondary to Bartonella henselae infectionAnna Catherine Kilonback, Catherine Guly, Jolanta Bernatoniene, et al.
American Journal of Ophthalmology|November 5, 2017
Uveitis and Juvenile Psoriatic Arthritis or PsoriasisSherveen S Salek, Archana Pradeep, Catherine Guly, et al.
Ocular Immunology and Inflammation|February 21, 2023
Childhood Chronic Idiopathic Uveitis in a Multicentre International CohortIlaria Maccora, Catherine Guly, Cinzia de Libero, et al.
Pediatric Rheumatology Online Journal|October 6, 2019
Same but different? A thematic analysis on adalimumab biosimilar switching among patients with juvenile idiopathic arthritisWilliam D Renton, Helen Leveret, Catherine Guly, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|February 10, 2026
Treatment of a large cohort of childhood chronic non-infectious uveitis a multicentric large study: adalimumab versus methotrexate as first line therapyIlaria Maccora, Catherine Guly, Cinzia de Libero, et al.
BMC Rheumatology|March 20, 2019
A phase II trial protocol of Tocilizumab in anti-TNF refractory patients with JIA-associated uveitis (the APTITUDE trial)Athimalaipet V Ramanan, Andrew D Dick, Ashley P Jones, et al.
Pageof 2